Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study rBV A/B-CL-001 is a Phase 2b, 2-part, open-label, uncontrolled study to evaluate safety, tolerability, and immunogenicity of a single dose of recombinant botulinum vaccine A/B (rBV A/B) for the production of BabyBIG in volunteers previously immunized with the pentavalent botulinum (PBT) toxoid. This study is designed to determine neutralizing antibody levels for botulinum toxin types A and B in healthy subjects who were previously immunized with the PBT for occupational protection and who receive the rBV A/B. Subjects with titers of the neutralizing antibodies against the toxins would be candidates for plasma donation for BabyBIG production.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®

NCT06112834

Botulism

COMPLETED PHASE2

Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®

NCT03676634

Botulism

COMPLETED PHASE2

Study of Human Botulism Immunoglobulin in Infants With Botulism

NCT00004401

Infant Botulism Botulism

COMPLETED NA

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

NCT00764634

Botulism Vaccine

COMPLETED PHASE2

Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults

NCT00098098

RECOMBINANT BOTULINUM VACCINE A/B

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Botulism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine

Group Type EXPERIMENTAL

rBV A/B

Intervention Type BIOLOGICAL

rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rBV A/B

rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The volunteer has received pentavalent botulinum toxoid for occupational protection under BB IND 0161, with the previous pentavalent botulinum toxoid dose at least 6 months prior to the planned rBV A/B dose.
* The volunteer is between the ages of 18 and 69 years at the time of consent.
* The volunteer is healthy and has an acceptable medical history.
* The volunteer meets the subject suitability requirements and recommendations for source plasma donors (for Part 2 subjects only).
* The volunteer, if female and of childbearing potential, is not pregnant or lactating, and agrees to use an acceptable form of FDA-approved contraception for the duration of the study.
* The volunteer has the ability to understand the requirements of the study and provide informed consent.
* The volunteer agrees to complete the subject diary on a daily basis for 7 days post-vaccination and to report concomitant medication and adverse events during the study period.
* The volunteer provides written authorization for use and disclosure of protected health information.
* The volunteer agrees not to donate blood or blood products (outside of study procedures) during the course of the study.
* The volunteer has personal health insurance.

Exclusion Criteria

* Be pregnant or nursing
* The volunteer has a history of laboratory evidence of syphilis, acquired immunodeficiency syndrome, Creutzfeldt-Jakob disease, or infection with human immunodeficiency viruses 1 or 2, human T cell lymphotropic virus 1, hepatitis B virus, or hepatitis C virus.
* The volunteer had prior severe local or severe systemic reaction to last immunization with pentavalent botulinum toxoid.
* The volunteer has a known allergy to aluminum compounds, yeast, or other components of the vaccine.
* The volunteer has donated one or more units of blood or undergone plasmapheresis within 28 days before screening.
* The volunteer has received a blood product or immunoglobulin within 6 months of screening or plans to receive such products during the study.
* The volunteer has received licensed nonliving vaccine within 14 days before study entry or licensed live vaccine within 60 days before study entry.
* The volunteer has received investigational products (drugs, biologics, vaccines, or implantable devices) 60 days prior to study entry or plans to receive experimental products at any time during the study.
* The volunteer has received prescription immunosuppressive or immunomodulatory agents, including parenteral, inhaled, or oral corticosteroids within 3 months before screening or plans on receiving such therapy at any time during the study with the exceptions (Subjects who have used prescription topical steroids may be enrolled 2 weeks after the therapy is completed; Intra-articular, bursal, or tendon injectable steroids are permitted; Any over-the-counter topical steroid use is permitted; Ophthalmic and intranasal steroids are permitted).
* The volunteer has received cytotoxic therapy at any time in the previous 5 years to study entry.
* The volunteer has an active systemic or recurrent disease that would place the subject at unacceptable risk of injury, require hospitalization, or require surgical intervention.
* The volunteer has a history of alcohol or drug abuse within 12 months before screening.
* The volunteer has past, present, or suspected illicit injection drug use.
* The volunteer has inflammatory, vasculitic, or rheumatic disease, including systemic lupus erythematosus, polymyalgia rheumatica, rheumatoid arthritis, or scleroderma.
* The volunteer has clinically recognized hepatic or renal insufficiency.
* The volunteer has uncontrolled hypertension.
* The volunteer has moderate to severe asthma, chronic obstructive pulmonary disease, or other significant pulmonary disease.
* The volunteer has a seizure disorder.
* The volunteer has moderate or severe illness or oral temperature of 100.4°F or greater within 3 days prior to immunization.
* The volunteer is determined by the investigator to be unsuitable for participation in this trial for any reason.

Minimum Eligible Age

18 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes